Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | MicrobiomeTrials
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
SUSPENDEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-15Est. Completion: 2033-12-30
Enrollment target: 30 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in